- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04298138
Dengue 3 Human Infection Model (DENV-3)
April 9, 2024 updated by: State University of New York - Upstate Medical University
Phase One, Open Label Assessment of a Dengue-3-Virus-Live Virus Human Challenge - (DENV-3-LVHC) Virus Strain
To evaluate the effectiveness of candidate dengue vaccine formulations, it is prudent to develop an appropriate challenge model.
This study will examine the safety and effectiveness of the Dengue 3 Live Virus Human Challenge (DENV-3-LVHC) product and assess the ability of this virus strain to elicit an uncomplicated dengue-like illness.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Healthy subjects between 18 and 45 years old will be inoculated with Dengue 3 Live Virus Human Challenge (DENV-3-LVHC) in a dose ranging study.
Subjects will be closely monitored for the first 28 days with continued follow up through 6 months.
Clinical and laboratory parameters, viremia and antibody levels will be assessed.
The goal is to determine the dose that produces uncomplicated dengue-like illness.
Study Type
Interventional
Enrollment (Actual)
9
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Syracuse, New York, United States, 13210
- State University of New York, Upstate Medical University (SUNY-UMU)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Age 18-45 at the time of consent
- Ability and willingness to sign informed consent
- Passing score on comprehension test of at least 75%, with up to 3 attempts
- Available for the study period
- Willing to use contraception for the duration of the study
- Provide consent for release of medical history records from primary care physician, college or university, urgent care or emergency room visit
Exclusion Criteria:
- Female: pregnant or lactating
- Heavy menstrual bleeding within the last 6 months- menstrual periods lasting longer than 6 days, or requiring 5 or more pads or tampons per day.
- Female subjects using an intrauterine device (IUD) or Mirena®
- Female subjects with fibroids or uterine polyps, endometriosis, adenomyosis, and uterine scarring (e.g., after D&C)
- Blood tests confirming infection with human immunodeficiency virus- 1 (HIV-1), hepatitis C, hepatitis B (assessed by HbsAg) virus, or positive antibodies to the flaviviruses (FV) dengue, West Nile, Yellow Fever, Japanese encephalitis, or Zika.
- Active Diabetes or active peptic ulcer disease (PUD)
- Chronic obstructive pulmonary disease (COPD) or coronary artery disease (CAD)
- Known or suspected congenital or acquired immunodeficiency; or receipt of immunomodulation therapy such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- Current, or a history of, auto-immune disease
- History of Guillain-Barré syndrome (GBS)
- Any history of FV infection or FV vaccination; or planned FV vaccination, outside the study protocol, during the study period
- Diagnosis with Bipolar Disorder or Schizophrenia, hospitalization in the past year for a mental health disorder, or any other psychiatric condition, which in the opinion of the investigator prevents the subject from participating in the study.
- Planned travel during the study period (180 days) which would interfere with the ability to complete all study visits
- Recent (in the past 4 weeks) travel to any dengue endemic area. These potential subjects may be eligible for enrollment a minimum of 4 weeks later
- Any laboratory abnormalities prior to inoculation for the tests specified in Table 18 and Table 19 of the protocol, that are considered by the investigator to be clinically significant except those listed in exclusion criteria 16
- Subjects with the following grade 2 or greater lab abnormalities: Creatinine; Liver Function Tests - ALT, AST; Hemoglobin (females and males); White Blood Cell (WBC) decrease; Platelets decreased; Prothrombin Time (PT); Partial Thromboplastin Time (PTT); Fibrinogen decrease
- Significant screening physical examination abnormalities at the discretion of the investigator
- Women who intend to become pregnant or men who intend to father a child during the study period (approximately 180 days)
- Hives, shortness of breath, swelling of the lips or throat, or hospitalization related to a previous vaccination or an allergy to specific medications/animals for which antigens may be in the virus preparations to include: shellfish allergy, fetal bovine serum, L-glutamine, neomycin and streptomycin
- Planning to donate blood in the 1 year following inoculation with dengue
- Recent blood donation within prior 56 days of inoculation
- Receipt of blood products or antibodies within 56 days of inoculation or during the study period
- Participation (active or follow-up phase) or planned participation in another vaccine, drug, medical device, or medical procedure clinical trial in the 4 weeks prior to this trial, during the trial, or 6 months following inoculation in this clinical trial
- Recent or scheduled receipt of any vaccine 4 weeks prior to or after virus inoculation
- Beliefs that bar the administration of blood products or transfusions
- Positive urine screen for cocaine, amphetamines, or opiates
- Currently taking Methadone or Suboxone
- Currently taking anti-coagulant medication, aspirin or non-steroidal anti-inflammatory drugs (NSAIDs)
- Chronic migraine headaches, defined as more than 15 headache days per month over a 3-month period of which more than 8 are migraines, in the absence of medication over use
- Chronic medical condition that, in the opinion of the investigator, impacts subject safety.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low dose DENV-3-LVHC
Dengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single low dose (0.5 mL of 1.4 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
|
Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489 administered as a single injection.
|
Experimental: Medium dose DENV-3-LVHC
Dengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single medium dose (0.5 mL of 1.4 x 10^4 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
|
Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489 administered as a single injection.
|
Experimental: High dose DENV-3-LVHC
Dengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single high dose (0.5 mL of 1.4 x 10^5 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
|
Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489 administered as a single injection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Serious Adverse Events
Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Total number
|
28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Number of Serious Adverse Events
Time Frame: 6 months post virus inoculation
|
Total number
|
6 months post virus inoculation
|
Number of Abnormal Laboratory Measurements
Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Total number of all abnormal labs
|
28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Intensity of Abnormal Laboratory Measurements
Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Graded according clinical laboratory normals and FDA toxicity scale
|
28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Duration of Abnormal Laboratory Measurements
Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Number of days of abnormal lab
|
28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Occurrence of Solicited Injection Site Symptoms
Time Frame: 7 days post virus inoculation
|
Number of solicited symptoms
|
7 days post virus inoculation
|
Intensity of Solicited Injection Site Symptoms
Time Frame: 7 days post virus inoculation
|
Graded according to FDA toxicity scale
|
7 days post virus inoculation
|
Duration of Solicited Injection Site Symptoms
Time Frame: 7 days post virus inoculation
|
Number of days per symptom
|
7 days post virus inoculation
|
Occurrence of Unsolicited Injection Site Symptoms
Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Number of unsolicited site symptoms
|
28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Intensity of Unsolicited Injection Site Symptoms
Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Graded according to FDA toxicity scale
|
28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Duration of Unsolicited Injection Site Symptoms
Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Number of days per symptom
|
28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Occurrence of Solicited Systemic Symptoms
Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Number of solicited systemic symptoms
|
28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Intensity of Solicited Systemic Symptoms
Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Graded according to FDA toxicity scale
|
28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Duration of Solicited Systemic Symptoms
Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Number of days per symptom
|
28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Occurence of Unsolicited Systemic Symptoms
Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Number of unsolicited systemic symptoms
|
28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Intensity of Unsolicited Systemic Symptoms
Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Graded according to FDA toxicity scale
|
28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Duration of Unsolicited Systemic Symptoms
Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Number of days per symptom
|
28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incubation period before onset of fever
Time Frame: Up to 28 days post virus inoculation
|
Number of days prior to fever
|
Up to 28 days post virus inoculation
|
Viremia by Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
Time Frame: Up to 28 days post virus inoculation
|
Levels of viremia
|
Up to 28 days post virus inoculation
|
Occurrence of Headache
Time Frame: Up to 28 days post virus inoculation
|
Number of headaches
|
Up to 28 days post virus inoculation
|
Grade of Headache
Time Frame: Up to 28 days post virus inoculation
|
Graded according to FDA toxicity scale
|
Up to 28 days post virus inoculation
|
Occurrence of Myalgia
Time Frame: Up to 28 days post virus inoculation
|
Number of reported myalgias
|
Up to 28 days post virus inoculation
|
Grade of Myalgia
Time Frame: Up to 28 days post virus inoculation
|
Graded according to FDA toxicity scale
|
Up to 28 days post virus inoculation
|
Occurrence of Rash
Time Frame: Up to 28 days post virus inoculation
|
Number of rashes
|
Up to 28 days post virus inoculation
|
Grade of Rash
Time Frame: Up to 28 days post virus inoculation
|
Graded according to FDA toxicity scale
|
Up to 28 days post virus inoculation
|
Occurrence of Abnormal Liver Function Test [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)]
Time Frame: Up to 28 days post virus inoculation
|
Number of abnormal liver function tests
|
Up to 28 days post virus inoculation
|
Grade of Abnormal Liver Function Test [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)]
Time Frame: Up to 28 days post virus inoculation
|
Graded according clinical laboratory normals and FDA toxicity scale
|
Up to 28 days post virus inoculation
|
Occurrence of Leukopenia
Time Frame: Up to 28 days post virus inoculation
|
Number of occurrences
|
Up to 28 days post virus inoculation
|
Grade of Leukopenia
Time Frame: Up to 28 days post virus inoculation
|
Graded according clinical laboratory normals and FDA toxicity scale
|
Up to 28 days post virus inoculation
|
Occurrence of Thrombocytopenia
Time Frame: Up to 28 days post virus inoculation
|
Number of occurrences
|
Up to 28 days post virus inoculation
|
Grade of Thrombocytopenia
Time Frame: Up to 28 days post virus inoculation
|
Graded according clinical laboratory normals and FDA toxicity scale
|
Up to 28 days post virus inoculation
|
Occurence of fever
Time Frame: Up to 28 days post virus inoculation
|
Defined as greater than or equal to 38°C (100.4°F)
measured at least 2 times in 24 hours but not lasting more than 72 hours
|
Up to 28 days post virus inoculation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Stephen J Thomas, MD, State University of New York, Upstate Medical University (SUNY-UMU)
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 3, 2020
Primary Completion (Actual)
December 14, 2021
Study Completion (Actual)
December 14, 2021
Study Registration Dates
First Submitted
February 21, 2020
First Submitted That Met QC Criteria
March 5, 2020
First Posted (Actual)
March 6, 2020
Study Record Updates
Last Update Posted (Actual)
April 11, 2024
Last Update Submitted That Met QC Criteria
April 9, 2024
Last Verified
June 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-01-UMU
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dengue
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesMexico
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseaseVietnam
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesPeru
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesSingapore
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesThailand
-
U.S. Army Medical Research and Development CommandGlaxoSmithKlineCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Shock SyndromePuerto Rico
-
University of the PhilippinesWorld Health Organization; University of North Carolina; International Vaccine... and other collaboratorsActive, not recruitingDengue | Dengue Fever | Severe Dengue | Virologically-confirmed Dengue
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue VirusPuerto Rico, Colombia, Mexico, Honduras
-
SanofiCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue VirusUnited States
-
SanofiCompletedDengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue VirusAustralia
Clinical Trials on Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
-
State University of New York - Upstate Medical...Walter Reed Army Institute of Research (WRAIR); U.S. Army Medical Research...Active, not recruiting
-
University of Maryland, BaltimoreMedical Technology Enterprise Consortium (MTEC)Completed
-
U.S. Army Medical Research and Development CommandState University of New York - Upstate Medical UniversityCompleted
-
State University of New York - Upstate Medical...U.S. Army Medical Research and Development Command; Janssen Pharmaceutica N...Completed
-
University of Maryland, BaltimoreUnited States Army Medical Materiel Development Activity; Medical Technology...CompletedDengueUnited States
-
SanofiCompletedDengue Fever | Dengue Hemorrhagic FeverPhilippines
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue | Dengue Fever | Dengue Hemorrhagic FeverIndonesia, Philippines, Malaysia, Thailand, Vietnam
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic FeverAustralia
-
Serum Institute of India Pvt. Ltd.PPD Australia Pty LtdCompleted
-
SanofiCompletedDengue Fever | Dengue Hemorrhagic FeverMalaysia